Barriers and facilitators to prescribing medicinal cannabis in New Zealand
The Journal of Primary Health Care · 30.06.2023 · 15 (2) · 135-146
DOI: 10.1071/hc22122 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Primary Health Care, online erschienen am 02.03.2023. Verfasst von Vinuli Withanarachchie und 2 weiteren Autor:innen. Beteiligte Einrichtung: Shore & Whariki Research Centre, College of Health, Massey University, Auckland, 1010, New Zealand. Hauptthemen laut MEDLINE: Medical Marijuana, General Practitioners. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
The New Zealand Medicinal Cannabis Scheme (NZMCS) was established in April 2020 with the aim of expanding access to quality controlled medicinal cannabis products and developing a domestic medicinal cannabis industry. Yet, two years later, many patients report challenges in utilising the NZMCS, including physicians’ reluctance to provide prescriptions for products.
Aim
To explore the barriers and facilitators to prescribing medicinal cannabis in New Zealand.
Methods
We conducted semi-structured interviews with 31 New Zealand physicians (general practitioners, specialists, and cannabis clinicians) who had discussed medicinal cannabis with patients in the last 6 months.
Results
Physicians reported the principal barrier to prescribing medicinal cannabis was the limited clinical evidence to support cannabis therapy. Further barriers included: a perceived lack of knowledge of medicinal cannabis; concerns over professional reputation; social stigma; and the price of products. Conversely, the factors that facilitated cannabis prescribing included patients’ and physicians’ knowledge of medicinal cannabis; some physicians’ desire to avoid patients having to engage with private cannabis clinics; and the timing of prescription requests (ie considering medicinal cannabis after other treatments had been exhausted).
Discussion
Further clinical research of medicinal cannabis medications, education and training, and information would support physicians to deliver more informed advice to patients and enhance professional confidence with cannabis therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shore & Whariki Research Centre, College of Health, Massey University, Auckland, 1010, New Zealand.
Zitieren
APA
Withanarachchie, V., Rychert, M., & Wilkins, C. (2023). Barriers and facilitators to prescribing medicinal cannabis in New Zealand. The Journal of Primary Health Care, 15(2), 135-146. https://doi.org/10.1071/hc22122
Vancouver
Withanarachchie V, Rychert M, Wilkins C. Barriers and facilitators to prescribing medicinal cannabis in New Zealand. The Journal of Primary Health Care. 2023;15(2):135-146. doi:10.1071/hc22122
BibTeX
@article{Withanarachchie2023,
author = {Withanarachchie, Vinuli and Rychert, Marta and Wilkins, Chris},
title = {Barriers and facilitators to prescribing medicinal cannabis in New Zealand},
journal = {The Journal of Primary Health Care},
year = {2023},
volume = {15},
number = {2},
pages = {135--146},
doi = {10.1071/hc22122}
}
EUVIMED